Skip to content
PICO Portalanswers from OpenAlex

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

PaperCitations, authors & open-access status

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes is a paper indexed in PICO Portal from OpenAlex.

How many citations does An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes have?

PICO Portalcitation count

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes has 1,141 citations in the OpenAlex counts PICO Portal stores.

When was An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes published?

PICO Portalyear

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes has 2019 year in the PICO Portal index.

What is the open-access status of An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes?

PICO Portaloa status

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes has bronze oa status in the PICO Portal index.

What is the DOI of An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes?

PICO Portaldoi

The DOI for An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes is on the source record.

What is the PMID of An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes?

PICO Portalpmid

The PMID for An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes is on the source record.

What is the OpenAlex record for An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes?

PICO Portalopenalex

The OpenAlex for An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial